Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $72.1 million.

  • Zentalis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 144.56% to $72.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.1 million, marking a year-over-year increase of 144.56%. This contributed to the annual value of $71.1 million for FY2024, which is 867.01% up from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Shares Outstanding (Diluted Average) is $72.1 million, which was up 144.56% from $72.0 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $72.1 million for Q3 2025, and its period low was $45.2 million during Q1 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $64.2 million, with a median of $70.6 million in 2023.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Shares Outstanding (Diluted Average) soared by 3101.63% in 2023, and later surged by 68.27% in 2025.
  • Zentalis Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $52.9 million in 2022, then grew by 23.75% to $65.4 million in 2023, then grew by 8.67% to $71.1 million in 2024, then grew by 1.49% to $72.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $72.1 million for Q3 2025, versus $72.0 million for Q2 2025 and $71.7 million for Q1 2025.